“The analytical technologies available for the monitoring of product- and process-related impurities in recombinant protein preparations have developed enormously in the last 10-20 years. However, these have not yet been fully harnessed to generate a complete picture of the mechanisms determining process and product impurities.”
The nature and fate of HCPs during downstream processing remains poorly characterised. At BioProduction this autumn, hear Professor Mark Smales from University of Kent discuss his findings of a proteomic approach for investigating the dynamics and fate of HCPs. He will reveal how these results and the knowledge gained can be used to screen cell lines or hosts to select those with reduced HCP profiles.
If you’d like more information about HCPs, CHO cells, antibody purification processes or mAbs then please visit the downloads section of our website for links to related articles